RTNS 2012

Recent articles

Spectrum from The Transmitter.

Better tools needed to assess clinical trials

The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.

By Emily Singer
14 May 2012 | 6 min read
Spectrum from The Transmitter.

Trials and tribulations

Clinical trials for fragile X drugs should include a behavioral therapy component, says a parent of a child with the disorder.

By Emily Singer
11 May 2012 | 3 min read
Spectrum from The Transmitter.

Compensatory mechanisms

Identifying genetic and other factors that protect children at risk of autism from developing the disorder could provide new avenues for treatment.

By Emily Singer
8 May 2012 | 3 min read
Spectrum from The Transmitter.

Debate over quality of adult-derived stem cells rages on

As the use of induced pluripotent stem cells grows, researchers are searching for ways to make them behave more predictably. 

By Emily Singer
7 May 2012 | 8 min read
Spectrum from The Transmitter.

Complex case

Multiple levels of complexity make it challenging to develop drugs to treat autism.

By Emily Singer
4 May 2012 | 3 min read
Spectrum from The Transmitter.

Fast-forward

In the last three years, autism researchers have gone from sequencing single genes to whole exomes, as highlighted at the Translational Neuroscience Symposium in Switzerland last week.

By Emily Singer
27 April 2012 | 3 min read

Explore more from The Transmitter

Two lab mice fighting.

From friend to foe: How the brain updates feelings toward others

A specific hippocampus-to-amygdala pathway reassigns emotional valence to a known individual, whereas the hippocampus’s own representation of that individual’s identity remains stable.

By Natalia Mesa
9 July 2026 | 5 min read
Illustration of scientist in lab coat looking at shelves of computer network models.

Mass-produced science is coming. What happens to scientists?

Artificial intelligence may soon enable researchers to generate high-quality science at a previously unimaginable speed. For science consumers—the public, medical patients, technology users—the likely effects will be positive. For scientists, the effects will be as disruptive as industrial mass production was for artisan manufacturers.

By Kenneth Harris
9 July 2026 | 9 min read
Adriano Aguzzi.

Neuropathologist not guilty of research misconduct, says university probe

The investigation determined that seven papers by corresponding author Adriano Aguzzi have “scientifically significant” errors, which Aguzzi attributes to his former students.

By Dalmeet Singh Chawla
8 July 2026 | 5 min read